Kamelija Žarković
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kamelija Žarković has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Anita Stojanović Marković
Laboratory for Oxidative Stress, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia
1 shared publication - Josipa Vlainić
Laboratory for Oxidative Stress, Institute Ruđer Bošković, Bijenička Cesta 54, 10000 Zagreb, Croatia
1 shared publication - Mirna Halasz
Laboratory for Oxidative Stress, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia
1 shared publication - Morana Jaganjac
Laboratory for Oxidative Stress, Division of Molecular Medicine, Ruder Boskovic Institute, Bijenicka 54, 10000 Zagreb, Croatia
1 shared publication - Neven Zarkovic
Laboratory for Oxidative Stress, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia
1 shared publication - Petra Jurešić
Division of Pathology, University Hospital Center Zagreb, 10000 Zagreb, Croatia
1 shared publication
Latest Publications
- Open Access
- 23 June 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (6) , 47727
Non-Enzymatic Lipid Peroxidation in Cancer Biology: An Overview
Cancer is characterized by a disrupted redox balance and impaired antioxidant defense, leading to the excessive production of reactive oxygen species (ROS) and oxidative stress. While moderate levels of ROS support tumor growth and adaptation, excessive oxidative stress induces lipid peroxidation (LPO), a self-catalyzed chain reaction that destroys cell membranes and generates reactive aldehydes. Among such reactive aldehydes, 4-hydroxynonenal (HNE) is considered a second messenger of ROS, exerting concentration- and context-dependent effects on cell proliferation, differentiation, apoptosis, immune modulation, and cell death. Since cancer cells are typically more sensitive to the cytotoxicity of HNE, it may also be considered not only a cofactor in carcinogenesis but also a natural factor in the organism’s defense against cancer. This paper provides a comprehensive overview of non-enzymatic LPO in cancer, highlighting its dual role in tumor promotion and suppression. We discuss how persistent oxidative stress, metabolic reprogramming, and remodeling of the tumor lipidome shape LPO dynamics and ferroptosis susceptibility within the tumor microenvironment, as well as the emerging therapeutic strategies that exploit LPO. Therefore, exploring the advantage of LPO’s dualistic nature may help to develop more individualized and efficient integrative biomedicine anticancer treatments.
- 23 June 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (6) , 47727
Open AccessNon-Enzymatic Lipid Peroxidation in Cancer Biology: An Overview
Cancer is characterized by a disrupted redox balance and impaired antioxidant defense, leading to the excessive production of reactive oxygen species (ROS) and oxidative stress. While moderate levels of ROS support tumor growth and adaptation, excessive oxidative stress induces lipid peroxidation (LPO), a self-catalyzed chain reaction that destroys cell membranes and generates reactive aldehydes. Among such reactive aldehydes, 4-hydroxynonenal (HNE) is considered a second messenger of ROS, exerting concentration- and context-dependent effects on cell proliferation, differentiation, apoptosis, immune modulation, and cell death. Since cancer cells are typically more sensitive to the cytotoxicity of HNE, it may also be considered not only a cofactor in carcinogenesis but also a natural factor in the organism’s defense against cancer. This paper provides a comprehensive overview of non-enzymatic LPO in cancer, highlighting its dual role in tumor promotion and suppression. We discuss how persistent oxidative stress, metabolic reprogramming, and remodeling of the tumor lipidome shape LPO dynamics and ferroptosis susceptibility within the tumor microenvironment, as well as the emerging therapeutic strategies that exploit LPO. Therefore, exploring the advantage of LPO’s dualistic nature may help to develop more individualized and efficient integrative biomedicine anticancer treatments.